These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 24016806)

  • 21. Isolation of Naturally Released Gonococcal Outer Membrane Vesicles as Vaccine Antigens.
    Francis IP; Lui X; Wetzler LM
    Methods Mol Biol; 2019; 1997():121-141. PubMed ID: 31119622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancement of adaptive immunity to Neisseria gonorrhoeae by local intravaginal administration of microencapsulated interleukin 12.
    Liu Y; Egilmez NK; Russell MW
    J Infect Dis; 2013 Dec; 208(11):1821-9. PubMed ID: 24048962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Problems posed by potential gonococcal vaccines viewed from the vantage point of a control agency.
    Robbins JB
    Br J Vener Dis; 1977 Jun; 53(3):170-2. PubMed ID: 406011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-β-dependent mechanisms.
    Liu Y; Islam EA; Jarvis GA; Gray-Owen SD; Russell MW
    Mucosal Immunol; 2012 May; 5(3):320-31. PubMed ID: 22354319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mucosal immunity in the genital tract: prospects for vaccines against sexually transmitted diseases--a review.
    Russell MW; Hedges SR; Wu HY; Hook EW; Mestecky J
    Am J Reprod Immunol; 1999 Jul; 42(1):58-63. PubMed ID: 10429768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and immune characterization of a novel Neisseria gonorrhoeae DNA vaccine using bacterial ghosts as vector and adjuvant.
    Jiao H; Yang H; Zhao D; Chen J; Zhang Q; Liang J; Yin Y; Kong G; Li G
    Vaccine; 2018 Jul; 36(30):4532-4539. PubMed ID: 29914847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vigorous response of human innate functioning IgM memory B cells upon infection by Neisseria gonorrhoeae.
    So NS; Ostrowski MA; Gray-Owen SD
    J Immunol; 2012 Apr; 188(8):4008-22. PubMed ID: 22427638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gonococcal microparticle vaccine in dissolving microneedles induced immunity and enhanced bacterial clearance in infected mice.
    Bagwe P; Bajaj L; Menon I; Braz Gomes K; Kale A; Patil S; Vijayanand S; Gala R; D'Souza MJ; Zughaier SM
    Int J Pharm; 2023 Jul; 642():123182. PubMed ID: 37369287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Murine host response to Neisseria gonorrhoeae upper genital tract infection reveals a common transcriptional signature, plus distinct inflammatory responses that vary between reproductive cycle phases.
    Francis IP; Islam EA; Gower AC; Shaik-Dasthagirisaheb YB; Gray-Owen SD; Wetzler LM
    BMC Genomics; 2018 Aug; 19(1):627. PubMed ID: 30134832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
    Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
    mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immunological mechanisms of Neisseria gonorrhoeae infection: An update].
    Li XC; Su XH
    Zhonghua Nan Ke Xue; 2018 May; 24(5):452-456. PubMed ID: 30171763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel gonorrhea vaccine composed of MetQ lipoprotein formulated with CpG shortens experimental murine infection.
    Sikora AE; Gomez C; Le Van A; Baarda BI; Darnell S; Martinez FG; Zielke RA; Bonventre JA; Jerse AE
    Vaccine; 2020 Dec; 38(51):8175-8184. PubMed ID: 33162204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA immunization of mice with a plasmid encoding Neisseria gonorrhea PorB protein by intramuscular injection and epidermal particle bombardment.
    Zhu W; Thomas CE; Sparling PF
    Vaccine; 2004 Jan; 22(5-6):660-9. PubMed ID: 14741158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategies for mimicking Neisserial saccharide epitopes as vaccines.
    Gulati S; Ngampasutadol J; Yamasaki R; McQuillen DP; Rice PA
    Int Rev Immunol; 2001; 20(2):229-50. PubMed ID: 11878767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MetQ of Neisseria gonorrhoeae Is a Surface-Expressed Antigen That Elicits Bactericidal and Functional Blocking Antibodies.
    Semchenko EA; Day CJ; Seib KL
    Infect Immun; 2017 Feb; 85(2):. PubMed ID: 27895130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Th1-polarized MtrE-based gonococcal vaccines display prophylactic and therapeutic efficacy.
    Song S; Wang S; Jiang X; Yang F; Gao S; Lin X; Cheng H; van der Veen S
    Emerg Microbes Infect; 2023 Dec; 12(2):2249124. PubMed ID: 37584947
    [No Abstract]   [Full Text] [Related]  

  • 37. Exploitation of
    Petousis-Harris H; Radcliff FJ
    Front Immunol; 2019; 10():683. PubMed ID: 31024540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of immune responses to gonococcal PorB delivered as outer membrane vesicles, recombinant protein, or Venezuelan equine encephalitis virus replicon particles.
    Zhu W; Thomas CE; Chen CJ; Van Dam CN; Johnston RE; Davis NL; Sparling PF
    Infect Immun; 2005 Nov; 73(11):7558-68. PubMed ID: 16239559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccines for gonorrhea: where are we on the curve?
    Blake MS; Wetzler LM
    Trends Microbiol; 1995 Dec; 3(12):469-74. PubMed ID: 8800838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The therapeutic efficacy of a gonococcal vaccine].
    Andreeva ZM; Bednova VN; Shevchenko NM; Malyshev AM; Danilenko TI
    Vestn Dermatol Venerol; 1989; (11):53-5. PubMed ID: 2515676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.